ALKERMES (NASDAQ:ALKS)
8.66
0.25 (2.81%)
| ALKERMES (NASDAQ:ALKS) Delayed : | |||||
|---|---|---|---|---|---|
| Previous Close | $8.91 | 52 Week High | $13.16 | ||
| Open | $8.89 | 52 Week Low | $5.55 | ||
| Day High | $8.99 | P/E | 10.31 | ||
| Day Low | $8.63 | EPS | $0.84 | ||
| Volume | 514,199 | ||||
| More ALKS Info: Chart SEC Filings Profile Historical Options | |||||
What is this?Friends, Peers and Foes
| Ticker | # Stories | Ticker | # Stories |
|---|---|---|---|
| AMLN | 14 | LLY | 13 |
| VRSN | 4 | NVO | 4 |
| MF | 4 | JDSU | 3 |
| SBUX | 3 | PSUN | 3 |
| AMLN | 3 | RRGB | 3 |
| CROX | 3 | PARD | 3 |
Entities who have mentioned ALKS
- Jefferies & Co | View Related Stories »
- Dividend | View Related Stories »
- Piper Jaffray | View Related Stories »
- Citi | View Related Stories »
- Morgan Stanley | View Related Stories »
- StreetInsider.com Morning Movers | View Related Stories »
- Robert W Baird | View Related Stories »
- Deutsche Bank | View Related Stories »
- Initial Jobless Claims | View Related Stories »
- Trading Radar | View Related Stories »
- UBS | View Related Stories »
- Rodman & Renshaw | View Related Stories »
- Kaufman Bros. | View Related Stories »
- Bear Stearns | View Related Stories »
- Roth Capital | View Related Stories »
- JPMorgan | View Related Stories »
- Unusual 11 Mid-Day Movers | View Related Stories »
- After-Hours Movers | View Related Stories »
- Banc of America | View Related Stories »
- Daniel Loeb | View Related Stories »
- Morgan Joseph | View Related Stories »
- Baupost Group | View Related Stories »
- Barclays | View Related Stories »
- Seth Klarman | View Related Stories »
- Lehman Brothers | View Related Stories »
View All Major News StreetInsider.com Major News for ALKS
- Alkermes (ALKS) Posts Q2 EPS of 1c, Tops by 10c; Guides FY09 Sales
- Alkermes (ALKS) Reports Q2 Earnings
- Alkermes (ALKS) Misses Q3 EPS by 4c, Revises FY09 Financials Lower
View All ReportsStreetInsider.com Reports on ALKS
- Notable Analyst Rating Changes 11/17: XOM, PALM, ALKS, ITW, SINA Upgraded; SPWRA, PARD, PSUN, JOYG Downgraded
- Morning Movers 11/17: ZOOM, SMTL, AGO, ABCW, XJT Higher; INOC, QUIK, PSUN, ERI, FTK, TBUS Lower
- Leerink Swann Upgrades Alkermes (ALKS) to Outperform; Significant Market Opportunity in Opioid Dependence
- Biotech Movers: SPEX, NABI, ALKS Up; PARD, CRXX Down
- Alkermes (ALKS) Reports Positive Preliminary Results from Phase 3 Trial of Naltrexone
View All Press ReleasesCompany Press Releases on ALKS
- Alkermes Initiates Phase 2 Clinical Study of ALKS 33 for the Treatment of Alcohol Dependence
- Alkermes Announces Positive Results from Phase 3 Clinical Study of Naltrexone for Extended-Release Injectable Suspension for the Treatment of Opioid Dependence
- Alkermes' Corporate Presentation to be Webcast at the Lazard Capital Markets Healthcare Conference
- Alkermes Reports Second Quarter Fiscal 2010 Financial Results
- Alkermes' Corporate Presentation to be Webcast at the Credit Suisse Healthcare Conference
StreetInsider Reports on ALKS by Category
View All BlogsBlogs on ALKS
- Tuesday's Big Gainers on Heavy Volume
- BioMed News Bytes: Cytori, Poniard, Alkermes, Spherix, CRXX, HGSI
- Wednesday Options Recap
- Three Recent Biotech Activist Wins by Carl Icahn
- Analyst upgrades, downgrades and initiations: BBBY, DLTR, ISLE, SEAC, WHR ...
View All FilingsSEC Filings on ALKS
- Form 4 ALKERMES INC For: Nov 18 Filed by: FRATES JAMES M
- Form 4 ALKERMES INC For: Nov 18 Filed by: LANDINE MICHAEL J
- Form 4 ALKERMES INC For: Nov 18 Filed by: BIBERSTEIN KATHRYN L
- Form 4 ALKERMES INC For: Nov 18 Filed by: Ehrich Elliot
- Form 4 ALKERMES INC For: Nov 18 Filed by: POPS RICHARD F
Comments on ALKS
No comments are currently available.
